Herceptin – Treatment of Her2-positive Breast Cancer

Herceptin - Treatment of Her2-positive Breast Cancer

Herceptin – treatment of HER2-positive breast cancer

Target therapy for breast cancer

Mammology – Breast surgery – Eurodoctor.ru – 2008

The term "target therapy" comes from the English target – target target. Thus, the target-therapy – a treatment of cancer, aimed at the specific parameters of cancer cells: proteins and enzymes that produce or the newly formed tumor blood vessels in tumors. In this target-therapy has no effect on normal healthy cells. Most drugs target-therapy have a similar effect of antibodies that are produced by the immune system. Therefore it is sometimes called the target of immune-therapy-therapy target. This distinguishes the mechanism of target-therapy on the mechanism of action of many anticancer drugs.

Herceptin – a very effective drug in the treatment of HER2-positive breast cancer in women in the II, III and IV stages of cancer. Herceptin is usually appointed by the intravenous injection once every 1 – 3 weeks. Herceptin is a so-called target-therapy, because it acts directly on tumor cells that produce excessive amounts of HER2-protein (protein). Such tumors are called HER2-positive.

Herceptin is also called targeted immune therapy, since its effect is similar to antibodies that block the HER2-protein in cancer cells. Approximately one in four breast cancer – HER2-positive. In addition, HER2-positive breast cancer has a more severe course.

Herceptin is prescribed only to patients with HER2-positive breast cancer. It is effective in the treatment of metastatic cancers as well as early forms of breast cancer.

Its action is as follows:

  • Reducing the size and the destruction of tumor cells spread beyond the breast.
  • Reducing the size of the tumor in the breast before surgery.
  • Reducing the risk of cancer recurrence after surgery in patients with average tumor size (two or more cm) or in the lymph node.

In the U.S., Herceptin is approved for use in the following cases:

  • Metastatic HER2-positive breast cancer.
  • In patients with early HER2-positive breast cancer as adjuvant therapy in combination with chemotherapy.

Breast Center Dr. FALBREDE – GERMANY

Mammology in MOSCOW – Medical Center Health Institute

Examination and treatment in GERMANY – Institute "DIAGNOSTIX"

History of the Herceptin
The mechanism of action of Herceptin
Indications for treatment with Herceptin
Side effects of Herceptin on the part of the heart and lungs
Combination therapy – the use of Herceptin with chemotherapy
Herceptin in the treatment of metastatic breast cancer